JP2002500180A - ジスルフィラムで構成される医薬品組成物 - Google Patents

ジスルフィラムで構成される医薬品組成物

Info

Publication number
JP2002500180A
JP2002500180A JP2000527235A JP2000527235A JP2002500180A JP 2002500180 A JP2002500180 A JP 2002500180A JP 2000527235 A JP2000527235 A JP 2000527235A JP 2000527235 A JP2000527235 A JP 2000527235A JP 2002500180 A JP2002500180 A JP 2002500180A
Authority
JP
Japan
Prior art keywords
disulfiram
disorder
pharmaceutical composition
cells
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000527235A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002500180A5 (enExample
Inventor
マリコブスキイ、モシェ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Publication of JP2002500180A publication Critical patent/JP2002500180A/ja
Publication of JP2002500180A5 publication Critical patent/JP2002500180A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
JP2000527235A 1998-01-11 1999-01-11 ジスルフィラムで構成される医薬品組成物 Pending JP2002500180A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL122892 1998-01-11
IL12289298A IL122892A0 (en) 1998-01-11 1998-01-11 Pharmaceutical compositions comprising a thiocarbamate
PCT/IL1999/000017 WO1999034784A2 (en) 1998-01-11 1999-01-11 Pharmaceutical compositions comprising disulfiram for inhibiting angiogenesis

Publications (2)

Publication Number Publication Date
JP2002500180A true JP2002500180A (ja) 2002-01-08
JP2002500180A5 JP2002500180A5 (enExample) 2006-02-23

Family

ID=11071076

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000527235A Pending JP2002500180A (ja) 1998-01-11 1999-01-11 ジスルフィラムで構成される医薬品組成物

Country Status (9)

Country Link
US (1) US6288110B1 (enExample)
EP (1) EP1047416B1 (enExample)
JP (1) JP2002500180A (enExample)
AT (1) ATE401879T1 (enExample)
AU (1) AU1888599A (enExample)
DE (1) DE69939155D1 (enExample)
DK (1) DK1047416T3 (enExample)
IL (1) IL122892A0 (enExample)
WO (1) WO1999034784A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013100268A (ja) * 2011-10-11 2013-05-23 Chiba Univ 肝がん幹細胞阻害剤
WO2021080363A1 (ko) * 2019-10-25 2021-04-29 연세대학교 산학협력단 암의 예방 또는 치료용 조성물
JP7193146B2 (ja) 2017-03-17 2022-12-20 国立大学法人大阪大学 光受容感度の抑制又は低減剤

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6589987B2 (en) 1998-09-08 2003-07-08 Charlotte-Mecklenburg Hospital Authority Method of treating cancer using tetraethyl thiuram disulfide
US6706759B1 (en) 1998-09-08 2004-03-16 Charlotte-Mecklenburg Hospital Authority Method of treating cancer using dithiocarbamate derivatives
US6548540B2 (en) * 1998-09-08 2003-04-15 Charlotte-Mecklenburg Hospital Authority Method of treating cancer using dithiocarbamate derivatives
US7816403B2 (en) * 1998-09-08 2010-10-19 University Of Utah Research Foundation Method of inhibiting ATF/CREB and cancer cell growth and pharmaceutical compositions for same
AU2002226650A1 (en) * 2001-01-18 2002-07-30 Arnold Hoffman Redox therapy for tumors
US20040157837A1 (en) * 2002-11-07 2004-08-12 Serbedzija George N. Combinations for the treatment of fungal infections
WO2007065167A1 (en) * 2005-12-02 2007-06-07 The Johns Hopkins University Use of high-dose oxazaphosphorine drugs for treating immune disorders
WO2008034074A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Cyclosphosphamide in combination with anti-idiotypic vaccines
WO2008034071A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Method of identifying patients suitable for high-dose cyclophosphamide treatment
WO2008034076A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Cyclophosphamide in combination with immune therapeutics
WO2008068746A2 (en) * 2006-12-04 2008-06-12 Yeda Research And Development Co. Ltd. Disulfiram doses and treatment regimen suitable for treatment of angiogenesis-dependent disorders
US9026372B2 (en) * 2007-11-21 2015-05-05 Accentia Biopharmaceuticals, Inc. Methods for providing a system of care for a high-dose oxazaphosphorine drug regimen
WO2009067699A2 (en) * 2007-11-21 2009-05-28 Accentia Biopharmaceuticals, Inc. Methods for providing a system of care for an oxazaphosphorine drug regimen
EP2632450A1 (en) * 2010-08-31 2013-09-04 Avidal Vascular GmbH Compositions comprising a taxane for coating medical devices
WO2014152207A1 (en) 2013-03-15 2014-09-25 Mylan Laboratories, Inc. Hot melt granulation formulations of poorly water-soluble active agents
WO2015120254A1 (en) * 2014-02-06 2015-08-13 Texas Tech University System Disulfiram compositions and treatments for brain tumors
GB201407806D0 (en) 2014-05-02 2014-06-18 Ucl Business Plc Treatment of fibrosis
GB201519643D0 (en) * 2015-11-06 2015-12-23 Univ Wolverhampton Disulfiram formulation
WO2017177947A1 (zh) 2016-04-13 2017-10-19 诺马（北京）科技有限公司 局部注射双硫仑制剂治疗胸腹膜癌症的方法
EP3311843A1 (en) 2016-10-13 2018-04-25 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Compositions comprising dithiocarbamate and cyclodextrin
EP3813805A4 (en) * 2018-06-27 2021-08-25 Children's Medical Center Corporation INFLAMMATION INHIBITION COMPOUNDS
US11311538B2 (en) 2018-07-13 2022-04-26 Yale University Compositions and methods for targeting cancers
EP3693740A1 (en) 2019-02-07 2020-08-12 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Improved dithiocarmabate based compounds, therapies and diagnostics
EP4135660A1 (en) * 2020-04-16 2023-02-22 Atossa Therapeutics, Inc. Compositions and methods to reduce the infectivity of a virus
WO2021231814A1 (en) * 2020-05-14 2021-11-18 The Trustees Of Columbia University In The City Of New York Compositions and methods for the treatment and prevention of vascular malformations
US12070468B2 (en) * 2020-05-14 2024-08-27 The Trustees Of Columbia University In The City Of New York Compositions and methods for the treatment and prevention of vascular malformations
WO2022061171A1 (en) * 2020-09-18 2022-03-24 Spring Discovery, Inc. Combination therapies with disulfiram
US11065214B1 (en) * 2020-09-18 2021-07-20 Spring Discovery, Inc. Combination therapies with disulfiram
CN114376997B (zh) * 2021-10-10 2023-04-28 深圳市人民医院 一种新型IRE1a抑制剂紫草素及与双硫仑协同抗肿瘤组合方式

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63258410A (ja) * 1987-03-17 1988-10-25 メレルダウファーマスーティカルズ　インコーポレーテッド インターロイキン−１の放出を抑制する組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870101A (en) * 1987-03-17 1989-09-26 Merrell Dow Pharmaceuticals Inc. Method of inhibiting interleukin-1 release
US5807884A (en) 1992-10-30 1998-09-15 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63258410A (ja) * 1987-03-17 1988-10-25 メレルダウファーマスーティカルズ　インコーポレーテッド インターロイキン−１の放出を抑制する組成物

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013100268A (ja) * 2011-10-11 2013-05-23 Chiba Univ 肝がん幹細胞阻害剤
JP7193146B2 (ja) 2017-03-17 2022-12-20 国立大学法人大阪大学 光受容感度の抑制又は低減剤
WO2021080363A1 (ko) * 2019-10-25 2021-04-29 연세대학교 산학협력단 암의 예방 또는 치료용 조성물

Also Published As

Publication number Publication date
WO1999034784A2 (en) 1999-07-15
IL122892A0 (en) 1998-08-16
WO1999034784A3 (en) 2000-09-08
EP1047416B1 (en) 2008-07-23
DE69939155D1 (de) 2008-09-04
EP1047416A2 (en) 2000-11-02
AU1888599A (en) 1999-07-26
ATE401879T1 (de) 2008-08-15
DK1047416T3 (da) 2008-11-17
US6288110B1 (en) 2001-09-11

Similar Documents

Publication Publication Date Title
US6288110B1 (en) Pharmaceutical compositions comprising disulfiram
JP4465672B2 (ja) 再狭窄の治療及び／又は予防用の医薬組成物並びにそれを調製するためのｔｔａの使用
Donker et al. The effect of indomethacin on kidney function and plasma renin activity in man
JP2806454B2 (ja) 脈管形成阻止剤
US5571523A (en) Antioxidant-induced apoptosis in vascular smooth muscle cells
US6407139B1 (en) Neovascularization inhibitor
US5516807A (en) Method for treating vascular proliferative disorders following balloon angioplasty
JP2021042248A (ja) Ｔｒｐｖ２受容体アゴニストを用いる拡張期心機能不全の治療
JP2002524408A (ja) 性的機能不全を治療するための製剤
JPH09505809A (ja) ヒドロキシカルバゾール化合物類による平滑筋移動および増殖の阻害
JP4466370B2 (ja) 過活動膀胱治療剤
CA2316303A1 (en) Suppressing agent of angiogenesis, containing dienogest as effective ingredient
Breckenridge et al. The effect of dopamine on renal blood flow in man
EP0612733B1 (en) Use of 5-amino-Phthaloylhydrazide as Anti-Hypoxic and defensive Agent
Warshawsky et al. Bilateral renal aspergillosis
Warres Urethral stricture following transurethral resection of the prostate
JP2002500170A (ja) サーラム（ｔｈｉｒａｍ）で構成される医薬品組成物
US7767694B2 (en) Pharmaceutical composition having prokinetic effect
WO1991019488A1 (en) REDUCTION OF CARDIOVASCULAR VESSEL OCCLUSIONS WITH ASCORBATE AND LIPOPROTEIN (a) BINDING INHIBITORS
EP1210086B1 (en) Use of halofuginone for treating urethral stricture
JP2548491B2 (ja) 内膜肥厚の予防、治療剤
RU2020931C1 (ru) Способ получения лекарственного средства для лечения язвенной болезни желудочно-кишечного тракта млекопитающих
JPH0383915A (ja) 経粘膜製剤
AU722807B2 (en) Neovascularization inhibitor
Fortner et al. Multidisciplinary Challenge of Pheochromocytoma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090821

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091116

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091218

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100120

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110125